1. Home
  2. LOB vs NTLA Comparison

LOB vs NTLA Comparison

Compare LOB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Live Oak Bancshares Inc.

LOB

Live Oak Bancshares Inc.

HOLD

Current Price

$37.86

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.14

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOB
NTLA
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
LOB
NTLA
Price
$37.86
$12.14
Analyst Decision
Buy
Buy
Analyst Count
5
23
Target Price
$43.00
$20.02
AVG Volume (30 Days)
159.7K
3.4M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
0.32%
N/A
EPS Growth
31.95
27.43
EPS
1.35
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
$35.52
N/A
Revenue Next Year
$16.03
$62.75
P/E Ratio
$28.05
N/A
Revenue Growth
N/A
16.92
52 Week Low
$29.36
$7.95
52 Week High
$44.53
$28.24

Technical Indicators

Market Signals
Indicator
LOB
NTLA
Relative Strength Index (RSI) 29.82 55.35
Support Level $37.47 $11.51
Resistance Level $38.34 $13.88
Average True Range (ATR) 0.78 0.52
MACD -0.07 0.05
Stochastic Oscillator 8.55 86.68

Price Performance

Historical Comparison
LOB
NTLA

About LOB Live Oak Bancshares Inc.

Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: